Tissue slice grafts: An in vivo model of human prostate androgen signaling

American Journal of Pathology

Volumn 177, Issue 1, 2010, Pages 229-239

  Zhao, Hongjuan ^a   Nolley, Rosalie ^a   Chen, Zuxiong ^a   Peehl, Donna M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; CASPASE 3; FLUTAMIDE; LEUPRORELIN; OXYGEN; TESTOSTERONE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NKX3.1; UNCLASSIFIED DRUG;

ABLATION THERAPY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER CELL; CELL COMPOSITION; CONTROLLED STUDY; EPITHELIUM CELL; HISTOLOGY; HUMAN; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NUTRIENT; PRIORITY JOURNAL; PROSTATE; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TESTOSTERONE BLOOD LEVEL; TISSUE GRAFT; TISSUE SLICE;

EID: 77954582489     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2010.090821     Document Type: Article

References (46)

1. Pienta KJ, Abate-Shen C, Agus DB, Attar RM, Chung LW, Greenberg NM, Hahn WC, Isaacs JT, Navone NM, Peehl DM, Simons JW, Solit DB, Soule HR, VanDyke TA, Weber MJ, Wu L, Vessella RL: The current state of preclinical prostate cancer animal models. Prostate 2008, 68:629-639
2. Sobel RE, Sadar MD: Cell lines used in prostate cancer research: a compendium of old and new lines, part 2. J Urol 2005, 173:360-372
3. Sobel RE, Sadar MD: Cell lines used in prostate cancer research: a compendium of old and new lines, part 1. J Urol 2005, 173:342-359
4. Peehl DM: Primary cell cultures as models of prostate cancer development. Endocr Relat Cancer 2005, 12:19-47
5. Lamb DJ, Zhang L: Challenges in prostate cancer research: animal models for nutritional studies of chemoprevention and disease progression. J Nutr 2005, 135:3009S-3015S
6. Shappell SB, Thomas GV, Roberts RL, Herbert R, Ittmann MM, Rubin MA, Humphrey PA, Sundberg JP, Rozengurt N, Barrios R, Ward JM, Cardiff RD: Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res 2004, 64:2270-2305
7. Garber K: From human to mouse and back: "tumorgraft" models surge in popularity. J Natl Cancer Inst 2009, 101:6-8
8. Garber K: Personal mouse colonies give hope for pancreatic cancer patients. J Natl Cancer Inst 2007, 99:105-107
9. Presnell SC, Werdin ES, Maygarden S, Mohler JL, Smith GJ: Establishment of short-term primary human prostate xenografts for the study of prostate biology and cancer. Am J Pathol 2001, 159:855-860 (Pubitemid 32851006)
10. Wang Y, Revelo MP, Sudilovsky D, Cao M, Chen WG, Goetz L, Xue H, Sadar M, Shappell SB, Cunha GR, Hayward SW: Development and characterization of efficient xenograft models for benign and malignant human prostate tissue. Prostate 2005, 64:149-159
11. Gray DR, Huss WJ, Yau JM, Durham LE, Werdin ES, Funkhouser WK, Jr., Smith GJ: Short-term human prostate primary xenografts: an in vivo model of human prostate cancer vasculature and angiogenesis. Cancer Res 2004, 64:1712-1721
12. Huss WJ, Gray DR, Werdin ES, Funkhouser WK, Jr., Smith GJ: Evidence of pluripotent human prostate stem cells in a human prostate primary xenograft model. Prostate 2004, 60:77-90
13. Staack A, Kassis AP, Olshen A, Wang Y, Wu D, Carroll PR, Grossfeld GD, Cunha GR, Hayward SW: Quantitation of apoptotic activity following castration in human prostatic tissue in vivo. Prostate 2003, 54:212-219
14. Richter E, Srivastava S, Dobi A: Androgen receptor and prostate cancer. Prostate Cancer Prostatic Dis 2007, 10:114-118
15. Sharifi N, Gulley JL, Dahut WL: Androgen deprivation therapy for prostate cancer. JAMA 2005, 294:238-244 (Pubitemid 41043794)
16. Kiviharju-af Hallstrom TM, Jaamaa S, Monkkonen M, Peltonen K, Andersson LC, Medema RH, Peehl DM, Laiho M: Human prostate epithelium lacks Wee1A-mediated DNA damage-induced checkpoint enforcement. Proc Natl Acad Sci USA 2007, 104:7211-7216
17. Blauer M, Tammela TL, Ylikomi T: A novel tissue-slice culture model for non-malignant human prostate. Cell Tissue Res 2008, 332:489-498
18. Parrish AR, Gandolfi AJ, Brendel K: Precision-cut tissue slices: applications in pharmacology and toxicology. Life Sci 1995, 57:1887-1901
19. Kochakian C: The rate of absorption and effects of testosterone propionate pellets on mice. Endocrinology 1941, 28:478-484
20. Ibrahim L, Wright EA: Effect of castration and testosterone propionate on mouse vibrissae. Br J Dermatol 1983, 108:321-326 (Pubitemid 13152549)
21. van Rijn RS, Simonetti ER, Hagenbeek A, Hogenes MC, de Weger RA, Canninga-van Dijk MR, Weijer K, Spits H, Storm G, van Bloois L, Rijkers G, Martens AC, Ebeling SB: A new xenograft model for graft-versus-host disease by intravenous transfer of human peripheral blood mononuclear cells in RAG2-/- gammac-/- double-mutant mice. Blood 2003, 102:2522-2531
22. Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF, Ailles LE: Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 2007, 104:973-978
23. Pathak AS, Pacificar JS, Shapiro CE, Williams SG: Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study. J Urol 2007, 177:2132-2135; discussion 2135
24. de Jong IJ, Eaton A, Bladou F: LHRH agonists in prostate cancer: frequency of treatment, serum testosterone measurement and castrate level; consensus opinion from a roundtable discussion. Curr Med Res Opin 2007, 23:1077-1080
25. Tamboli P, Amin MB, Schultz DS, Linden MD, Kubus J: Comparative analysis of the nuclear proliferative index (Ki-67) in benign prostate, prostatic intraepithelial neoplasia, and prostatic carcinoma. Mod Pathol 1996, 9:1015-1019
26. Zeng L, Rowland RG, Lele SM, Kyprianou N: Apoptosis incidence and protein expression of p53, TGF-beta receptor II, p27Kip1, and Smad4 in benign, premalignant, and malignant human prostate. Hum Pathol 2004, 35:290-297
27. Mogal AP, van der Meer R, Crooke PS, Abdulkadir SA: Haploin-sufficient prostate tumor suppression by Nkx3.1: a role for chromatin accessibility in dosage-sensitive gene regulation. J Biol Chem 2007, 282:25790-25800
28. Lei Q, Jiao J, Xin L, Chang CJ, Wang S, Gao J, Gleave ME, Witte ON, Liu X, Wu H: NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss. Cancer Cell 2006, 9:367-378
29. Wang X, Kruithof-de Julio M, Economides KD, Walker D, Yu H, Halili MV, Hu YP, Price SM, Abate-Shen C, Shen MM: A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature 2009, 461:495-500
30. Leong KG, Wang BE, Johnson L, Gao WQ: Generation of a prostate from a single adult stem cell. Nature 2008, 456:804-808
31. Garmey EG, Sartor O, Halabi S, Vogelzang NJ: Second-line chemotherapy for advanced hormone-refractory prostate cancer. Clin Adv Hematol Oncol 2008, 6:118-122, 127-132
32. Suzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S, Matsumoto T, Fujii M, Takihana Y, Usui T, Matsuda T, Ozono S, Kumon H, Ichikawa T, Miki T: Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. J Urol 2008, 180:921-927
33. Jayachandran J, Freedland SJ: Prevention of prostate cancer: what we know and where we are going. Am J Mens Health 2008, 2:178-189
34. Sarvis JA, Thompson IM: Prostate cancer chemoprevention: update of the prostate cancer prevention trial findings and implications for clinical practice. Curr Oncol Rep 2008, 10:529-532
35. Chung LW, Baseman A, Assikis V, Zhau HE: Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. J Urol 2005, 173:10-20 (Pubitemid 39627663)
36. Buijs JT, van der Pluijm G: Osteotropic cancers: from primary tumor to bone. Cancer Lett 2009, 273:177-193
37. Mohler JL, Gregory CW, Ford OH, 3rd, Kim D, Weaver CM, Petrusz P, Wilson EM, French FS: The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004, 10:440-448 (Pubitemid 38173980)
38. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD, Nelson PS: Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008, 68:4447-4454
39. Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, Ettinger SL, Gleave ME, Nelson CC: Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 2008, 68:6407-6415
40. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, Febbo PG, Balk SP: Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006, 66:2815-2825
41. Wako K, Kawasaki T, Yamana K, Suzuki K, Jiang S, Umezu H, Nishiyama T, Takahashi K, Hamakubo T, Kodama T, Naito M: Expression of androgen receptor through androgen-converting enzymes is associated with biological aggressiveness in prostate cancer. J Clin Pathol 2008, 61:448-454
42. Donovan MJ, Osman I, Khan FM, Vengrenyuk Y, Capodieci P, Koscuiszka M, Anand A, Cordon-Cardo C, Costa J, Scher HI: Androgen receptor expression is associated with prostate cancer-specific survival in castrate patients with metastatic disease. BJU Int 2010, 105:462-467
43. Chang SS, Reuter VE, Heston WD, Hutchinson B, Grauer LS, Gaudin PB: Short term neoadjuvant androgen deprivation therapy does not affect prostate specific membrane antigen expression in prostate tissues. Cancer 2000, 88:407-415 (Pubitemid 30051827)
44. Bass R, Perry B, Langenstroer P, Thrasher JB, Dennis KL, Tawfik O, Holzbeierlein J: Effects of short-term finasteride on apoptotic factors and androgen receptors in prostate cancer cells. J Urol 2009, 181: 615-619; discussion 619-620
45. Armas OA, Aprikian AG, Melamed J, Cordon-Cardo C, Cohen DW, Erlandson R, Fair WR, Reuter VE: Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma. Am J Surg Pathol 1994, 18:979-991
46. Vailancourt L, Ttu B, Fradet Y, Dupont A, Gomez J, Cusan L, Suburu ER, Diamond P, Candas B, Labrie F: Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma: a randomized study. Am J Surg Pathol 1996, 20:86-93